Evaluation by lymphoscintigraphy of the effect of a micronized flavonoid fraction (Daflon 500 mg) in the treatment of upper limb lymphedema.
Identifieur interne : 000927 ( France/Analysis ); précédent : 000926; suivant : 000928Evaluation by lymphoscintigraphy of the effect of a micronized flavonoid fraction (Daflon 500 mg) in the treatment of upper limb lymphedema.
Auteurs : A P Pecking [France]Source :
- International angiology : a journal of the International Union of Angiology [ 0392-9590 ] ; 1995.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Bras, Diosmine (administration et posologie), Diosmine (usage thérapeutique), Femelle, Humains, Lymphoedème (imagerie diagnostique), Lymphoedème (traitement médicamenteux), Lymphoedème (étiologie), Lymphoscintigraphie, Mastectomie (effets indésirables), Projets pilotes, Système lymphatique (), Tumeurs du sein (), Études de suivi.
- MESH :
- administration et posologie : Diosmine.
- effets indésirables : Mastectomie.
- imagerie diagnostique : Lymphoedème.
- traitement médicamenteux : Lymphoedème.
- usage thérapeutique : Diosmine.
- étiologie : Lymphoedème.
- Adulte, Adulte d'âge moyen, Bras, Femelle, Humains, Lymphoscintigraphie, Projets pilotes, Système lymphatique, Tumeurs du sein, Études de suivi.
English descriptors
- KwdEn :
- Adult, Arm, Breast Neoplasms (surgery), Diosmin (administration & dosage), Diosmin (therapeutic use), Female, Follow-Up Studies, Humans, Lymphatic System (drug effects), Lymphedema (diagnostic imaging), Lymphedema (drug therapy), Lymphedema (etiology), Lymphoscintigraphy, Mastectomy (adverse effects), Middle Aged, Pilot Projects.
- MESH :
- chemical , administration & dosage : Diosmin.
- adverse effects : Mastectomy.
- diagnostic imaging : Lymphedema.
- drug effects : Lymphatic System.
- drug therapy : Lymphedema.
- etiology : Lymphedema.
- surgery : Breast Neoplasms.
- chemical , therapeutic use : Diosmin.
- Adult, Arm, Female, Follow-Up Studies, Humans, Lymphoscintigraphy, Middle Aged, Pilot Projects.
Abstract
Upper limb lymphedema after conventional treatment of breast cancer occurs in about 20% of all treated cases, even after conservative therapy. Women with mild to severe upper limb lymphedema expect a decongestive therapy, which usually associates physiotherapy and medical treatment. Upper limb lymphoscintigraphy using rhenium colloids labelled with technetium 99m can be used as a lymphatic functional test in order to evaluate the efficacy of a therapy. We report here the results of a pilot, open study carried out on 10 female patients, age ranging from 44 to 64 years, previously treated for a breast cancer. The average time delay for the occurrence [correction of occurence] of lymphedema was 17 +/- 7 months. All patients received 500 mg twice daily of a micronized flavonoid fraction (Daflon 500 mg) for 6 months. At the end of the study, all patients had a clinical improvement of symptoms and limb volume and the mean decrease in volume of the swollen limb reached 6.80%. Functional parameters (half-life, clearance and lymphatic speed of the colloid) assessed with scintigraphy were significantly improved. These preliminary results suggest that this therapy is effective for the treatment of lymphedemas.
PubMed: 8919264
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 005320
- to stream PubMed, to step Curation: 005320
- to stream PubMed, to step Checkpoint: 005320
- to stream Ncbi, to step Merge: 00B872
- to stream Ncbi, to step Curation: 00B872
- to stream Ncbi, to step Checkpoint: 00B872
- to stream Main, to step Merge: 00CB97
- to stream Main, to step Curation: 00C303
- to stream Main, to step Exploration: 00C303
- to stream France, to step Extraction: 000927
Links to Exploration step
pubmed:8919264Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation by lymphoscintigraphy of the effect of a micronized flavonoid fraction (Daflon 500 mg) in the treatment of upper limb lymphedema.</title><author><name sortKey="Pecking, A P" sort="Pecking, A P" uniqKey="Pecking A" first="A P" last="Pecking">A P Pecking</name><affiliation wicri:level="1"><nlm:affiliation>Centre Rene Huguenin, Department of Nuclear Medicine, Saint Cloud, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Rene Huguenin, Department of Nuclear Medicine, Saint Cloud</wicri:regionArea><wicri:noRegion>Saint Cloud</wicri:noRegion><wicri:noRegion>Saint Cloud</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995</date><idno type="RBID">pubmed:8919264</idno><idno type="pmid">8919264</idno><idno type="wicri:Area/PubMed/Corpus">005320</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005320</idno><idno type="wicri:Area/PubMed/Curation">005320</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005320</idno><idno type="wicri:Area/PubMed/Checkpoint">005320</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005320</idno><idno type="wicri:Area/Ncbi/Merge">00B872</idno><idno type="wicri:Area/Ncbi/Curation">00B872</idno><idno type="wicri:Area/Ncbi/Checkpoint">00B872</idno><idno type="wicri:doubleKey">0392-9590:1995:Pecking A:evaluation:by:lymphoscintigraphy</idno><idno type="wicri:Area/Main/Merge">00CB97</idno><idno type="wicri:Area/Main/Curation">00C303</idno><idno type="wicri:Area/Main/Exploration">00C303</idno><idno type="wicri:Area/France/Extraction">000927</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation by lymphoscintigraphy of the effect of a micronized flavonoid fraction (Daflon 500 mg) in the treatment of upper limb lymphedema.</title><author><name sortKey="Pecking, A P" sort="Pecking, A P" uniqKey="Pecking A" first="A P" last="Pecking">A P Pecking</name><affiliation wicri:level="1"><nlm:affiliation>Centre Rene Huguenin, Department of Nuclear Medicine, Saint Cloud, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Rene Huguenin, Department of Nuclear Medicine, Saint Cloud</wicri:regionArea><wicri:noRegion>Saint Cloud</wicri:noRegion><wicri:noRegion>Saint Cloud</wicri:noRegion></affiliation></author></analytic><series><title level="j">International angiology : a journal of the International Union of Angiology</title><idno type="ISSN">0392-9590</idno><imprint><date when="1995" type="published">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Arm</term><term>Breast Neoplasms (surgery)</term><term>Diosmin (administration & dosage)</term><term>Diosmin (therapeutic use)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymphatic System (drug effects)</term><term>Lymphedema (diagnostic imaging)</term><term>Lymphedema (drug therapy)</term><term>Lymphedema (etiology)</term><term>Lymphoscintigraphy</term><term>Mastectomy (adverse effects)</term><term>Middle Aged</term><term>Pilot Projects</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Bras</term><term>Diosmine (administration et posologie)</term><term>Diosmine (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Lymphoedème (imagerie diagnostique)</term><term>Lymphoedème (traitement médicamenteux)</term><term>Lymphoedème (étiologie)</term><term>Lymphoscintigraphie</term><term>Mastectomie (effets indésirables)</term><term>Projets pilotes</term><term>Système lymphatique ()</term><term>Tumeurs du sein ()</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diosmin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diosmine</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Mastectomy</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lymphatic System</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Mastectomie</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diosmin</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diosmine</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Arm</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymphoscintigraphy</term><term>Middle Aged</term><term>Pilot Projects</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Bras</term><term>Femelle</term><term>Humains</term><term>Lymphoscintigraphie</term><term>Projets pilotes</term><term>Système lymphatique</term><term>Tumeurs du sein</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Upper limb lymphedema after conventional treatment of breast cancer occurs in about 20% of all treated cases, even after conservative therapy. Women with mild to severe upper limb lymphedema expect a decongestive therapy, which usually associates physiotherapy and medical treatment. Upper limb lymphoscintigraphy using rhenium colloids labelled with technetium 99m can be used as a lymphatic functional test in order to evaluate the efficacy of a therapy. We report here the results of a pilot, open study carried out on 10 female patients, age ranging from 44 to 64 years, previously treated for a breast cancer. The average time delay for the occurrence [correction of occurence] of lymphedema was 17 +/- 7 months. All patients received 500 mg twice daily of a micronized flavonoid fraction (Daflon 500 mg) for 6 months. At the end of the study, all patients had a clinical improvement of symptoms and limb volume and the mean decrease in volume of the swollen limb reached 6.80%. Functional parameters (half-life, clearance and lymphatic speed of the colloid) assessed with scintigraphy were significantly improved. These preliminary results suggest that this therapy is effective for the treatment of lymphedemas.</div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Pecking, A P" sort="Pecking, A P" uniqKey="Pecking A" first="A P" last="Pecking">A P Pecking</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000927 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000927 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= France
|étape= Analysis
|type= RBID
|clé= pubmed:8919264
|texte= Evaluation by lymphoscintigraphy of the effect of a micronized flavonoid fraction (Daflon 500 mg) in the treatment of upper limb lymphedema.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i -Sk "pubmed:8919264" \
| HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |